瑞德西韦（remdesivir）在第三阶段的试验中显示出药效的局限性

吉利德（Gilead）公司的新冠治疗药物瑞德西韦（remdesivir）已被认为是治疗新冠一个可行的疗法，也被视为经济能够重新开放的一个标志。美国、中国和世界其他地区的一些卫生当局也一直在使用remdesivir，此药也被视为可能能够治疗埃博拉病毒的一种药物，并希望该药能改善新冠患者的治疗效果。

但瑞德西韦在第三阶段试验中，显示了其药效的局限性，此试验只针对中度患者，重病患者并不在试验范围内。试验中的中度新冠患者被随机分配到服用瑞德西韦5天的组、服用瑞德西韦10天的组，以及接受普通护理的组，观察并评估其疗效。结果显示，接受5天瑞德西韦治疗的患者恢复效果最好，比接受一般护理的中度患者略有改善。但另一组接受药物治疗10天的中度患者却没有显著改善，总体来说每组患者恢复效果差异不大，但在新的试验中，服药的两组都没有发现新的安全风险。

Brigham and Women's医院的传染病医生、试验研究者Francisco Marty表示，瑞德西韦针对中度患者治疗的最新结果表明，如果患者能在疾病早期开始5天的治疗疗程，临床疗效可以有较显著的改善。这次试验的结果不难看出，瑞德西韦抗击新冠的效果并没有大家想象的那么有效，虽能够在一定条件下起到一些改善，但还算不上是抗击新冠的普遍特效药。而这一试验结果也导致吉利德股票下跌2.8%，至75.68美元。

Some health authorities in the U.S., China, and other parts of the world have been using remdesivir. This drug is also considered to be a drug that may be able to treat Ebola virus. It is hoped that this drug will improve the therapeutic effect of Covid-19 patients. Gilead's new crown treatment drug remdesivir has been regarded as a feasible treatment for the new crown, and is also regarded as a sign that the economy can reopen.

However, in the third phase of the study, remdesivir showed the limitations of its drug efficacy. This test is only for moderate patients, and serious patients are not within the scope of the trial. Patients with moderate coronavirus in the trial were randomly assigned to the group taking remdesivir for 5 days, or the group taking Radecivir for 10 days, and the group receiving general care to observe and evaluate their efficacy. The results showed that the patients who received 5 days of remdesivir had the best recovery effect, which was slightly better than the moderate patients who received general care, but the other group of patients who received medication for 10 days did not improve significantly. Overall The recovery effect of each group of patients is not much different, but in the new trial, no new safety risks were found in the two groups taking the drug.

Francisco Marty, an infectious disease doctor and trial investigator at Brigham and Women's Hospital, said that the latest results of Ridesivir treatment for moderate patients indicate that if patients can start a 5-day course of treatment early in the disease, the clinical effect can be more significantly improved. The results of this experiment are not difficult to see. The effect of remdesivir against the coronavirus is not as effective as everyone thinks, and the results of this test also caused Gilead's stock to fall 2.8% to $ 75.68.  source

指尖新闻：高信噪比，一目了然

新冠疫情追踪

现在在美国还有人care什么时候reopen吗。。。

再不开，美国就要垮了